BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Villeneuve S" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions | Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM; | 41916976 PSYCHOLOGY |
| 2 | Biomarkers | Zhou J; Wearn A; Huck J; Hughes CS; Baracchini G; Sylvain E; Tremblay-Mercier J; Poirier J; Breitner JCSCS; Villeneuve S; Chakravarty MM; Tardif CL; Gauthier CJ; Daugherty AM; Turner GR; Spreng RN; | 41499788 ENCS |
| 3 | Drug Development | Cunningham NP; Tremblay-Mercier J; Baril AA; Dang-Vu TT; Lim A; Geddes MR; Badawy M; Poirier J; Ducharme S; Villeneuve S; | 41450269 CONCORDIA |
| 4 | Longitudinal effects of cerebrovascular reactivity and cerebral pulsatility in cognitively intact older adults with APOE4: links with cognition | Potvin-Jutras Z; Tremblay PL; Mohammadi H; Villeneuve S; Spreng RN; Gauthier CJ; | 41353310 SOH |
| 5 | The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe | 41020412 SOH |
| 6 | The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S | 40778177 PSYCHOLOGY |
| 7 | Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions | Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM; | 40585093 PSYCHOLOGY |
| 8 | Longitudinal relationships among cerebrospinal fluid biomarkers, cerebral blood flow, and grey matter volume in individuals with a familial history of Alzheimer s disease | Sanami S; Intzandt B; Huck J; Villeneuve S; Iturria-Medina Y; Gauthier CJ; Prevent-Ad Research Group None; | 40347524 CONCORDIA |
| 9 | Sex and APOE4-specific links between cardiometabolic risk factors and white matter alterations in individuals with a family history of Alzheimer s disease | Tremblay SA; Nathan Spreng R; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ; | 40086421 PSYCHOLOGY |
| 10 | Alzheimer's Imaging Consortium | Tremblay SA; Spreng RN; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ; | 39782998 CONCORDIA |
| 11 | Biomarkers | Tremblay SA; Spreng RN; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ; | 39785351 CONCORDIA |
| 12 | Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status | Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN; | 38830849 SOH |
| 13 | Iron Deposition and Distribution Across the Hippocampus Is Associated with Pattern Separation and Pattern Completion in Older Adults at Risk for Alzheimer's Disease | Zhou J; Wearn A; Huck J; Hughes C; Baracchini G; Tremblay-Mercier J; Poirier J; Villeneuve S; Tardif CL; Chakravarty MM; Daugherty AM; Gauthier CJ; Turner GR; Spreng RN; | 38388425 PSYCHOLOGY |
| Title: | Drug Development | ||||
| Authors: | Cunningham NP, Tremblay-Mercier J, Baril AA, Dang-Vu TT, Lim A, Geddes MR, Badawy M, Poirier J, Ducharme S, Villeneuve S | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41450269/ | ||||
| DOI: | 10.1002/alz70859_105733 | ||||
| Publication: | Alzheimer s & dementia : the journal of the Alzheimer s Association | ||||
| Keywords: | |||||
| PMID: | 41450269 | Category: | Date Added: | 2025-12-26 | |
| Dept Affiliation: |
CONCORDIA
1 Douglas Mental Health University Institute, Montreal, QC, Canada. 2 Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD Centre), Montreal, QC, Canada. 3 Center for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, CIUSSS-NIM, Montreal, QC, Canada. 4 Université de Montréal, Montreal, QC, Canada. 5 Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montreal, QC, Canada. 6 Concordia University, Montreal, QC, Canada. 7 University of Toronto, Toronto, ON, Canada. 8 Montreal Neurological Institute, McGill University, Montreal, QC, Canada. 9 McGill University, Montreal, QC, Canada. |
||||
Description: |
Background: Poor sleep is a modifiable factor associated with the development and progression of Alzheimer's Disease (AD). Pharmacological treatments and Cognitive Behavioural Therapy for Insomnia (CBT-I) which promote sleep have the potential to improve AD risk profile. In addition, prior research suggests that Dual Orexin Receptor Antagonists (DORAs), which are prescribed more and more to treat insomnia, could also help to decrease tau phosphorylation and concentrations of beta-amyloid (Aß) in the cerebrospinal fluid. Objective: To study the impact of Lemborexant, a DORA, with or without CBT-I on AD blood biomarkers and on cognitive performance in a population at risk of developing AD dementia. Method: We will conduct a double-blind randomized clinical trial in men and women aged 50 to 90 years old with symptoms of insomnia. 220 participants will be screened and randomized into 4 treatment groups over 12 months: Lemborexant, Lemborexant plus CBT-I, placebo, or placebo plus CBT-I. All participants will receive education on sleep hygiene measures. Primary outcomes: Change in (1) plasma p-tau181 and (2) modified Preclinical Alzheimer's Cognitive Composite score from baseline to 12-months. Secondary outcomes: Change in (1) plasma p-tau217, (2) CSF Aß 42/40 and CSF p-tau181, and (3) objective sleep measures measured with electroencephalogram (EEG) recording from baseline to 12-months. Anticipated results: We anticipate that Lemborexant will be associated with a reduction in plasma p-tau181 over time compared to placebo. Lemborexant will improve sleep and cognitive performance compared to placebo, and the addition of CBT-I will accentuate the beneficial effect on sleep and cognition but not on AD biomarkers. Conclusion: This study will grant us an opportunity to deepen our understanding of the therapeutic potential of sleep interventions and the influence of DORAs on AD prevention. |
